Published in final edited form as:

Biochem Pharmacol. 2013 October 15; 86(8): 1074–1083. doi:10.1016/j.bcp.2013.07.031.

Transcriptional regulation by nicotine in dopaminergic neurons

Beverley M. Henley^{}, Brian A. Williams, Rahul Srinivasan, Bruce N. Cohen, Cheng Xiao, Elisha D.W. Mackey, Barbara J. Wold, and Henry A. Lester^{*}**

California Institute of Technology, 156-29 Caltech, Pasadena, CA 91125, USA

Abstract

Dopaminergic neurons in the substantia nigra pars compacta (SNc) degenerate in Parkinson's disease. These neurons robustly express several nicotinic acetylcholine receptor (nAChR) subtypes. Smoking appears to be neuroprotective for Parkinson's disease but the mechanism is unknown. To determine whether chronic nicotine-induced changes in gene expression contribute to the neuroprotective effects of smoking, we develop methods to measure the effect of prolonged nicotine exposure on the SNc neuronal transcriptome in an unbiased manner. Twenty neurons were collected using laser-capture microscopy and transcriptional changes were assessed using RNA deep sequencing. These results are the first whole-transcriptome analyses of chronic nicotine treatment in SNc neurons. Overall, 129 genes were significantly regulated: 67 upregulated, 62 downregulated. Nicotine-induced relief of endoplasmic reticulum (ER) stress has been postulated as a potential mechanism for the neuroprotective effects of smoking. Chronic nicotine did not significantly affect the expression of ER stress-related genes, nor of dopamine-related or nAChR genes, but it did modulate expression of 129 genes that could be relevant to the neuroprotective effects of smoking, including genes involved in (1) the ubiquitin–proteasome pathway, (2) cell cycle regulation, (3) chromatin modification, and (4) DNA binding and RNA regulation. We also report preliminary transcriptome data for single-cell dopaminergic and GABAergic neurons isolated from midbrain cultures. These novel techniques will facilitate advances in understanding the mechanisms taking place at the cellular level and may have applications elsewhere in the fields of neuroscience and molecular biology. The results give an emerging picture of the role of nicotine on the SNc and on dopaminergic neurons.

Keywords

Nicotinic acetylcholine receptor; RNA-Seq; Substantia nigra pars compacta; Dopamine-related genes; Ubiquitin–proteasome pathway

1. Introduction

Nicotine is the major addictive compound in tobacco, affecting ~20% of the world's population which in turn results in five million deaths worldwide each year [1]. Inhaled nicotine is efficiently delivered to the central nervous system where it affects various molecular and cellular processes [2,3]. In the brain, nicotine selectively interacts with its central targets, the nicotinic acetylcholine receptors (nAChRs). The 12 nAChR subunits combine in a variety of stoichiometries to form pentameric ligand-gated cation channels. The multiple subtypes of nAChRs bind nicotine, but with a range of affinities. Nicotine binds to and activates some nAChR subtypes (high-sensitivity nAChRs) more than others

nAChRs (low-sensitivity nAChRs), and can result in activation, then desensitization, of nAChRs. Another level of complexity of the actions of nicotine arises from the widespread and non-uniform distribution of nAChR subtypes throughout the brain [2]. Hence, nicotine influences many centrally regulated functions, in addition to the reward systems. In addition to the commonly reported changes in nicotinic acetylcholine receptors (nAChRs) [4–10], chronic nicotine exposure also leads to transcriptional changes throughout the brain [11–15]. Given the complexity of these interactions it is unsurprising that much remains to be learned about the effects, transcriptional and otherwise, of nicotine on the brain.

The substantia nigra pars compacta (SNc) dopaminergic neurons robustly express several nAChR receptor subtypes [16]. Nicotine exposure activates SNc nAChRs at the plasma membrane, increasing firing frequency and therefore resulting in release of dopamine in the dorsal striatum. The best-studied effect of chronic nicotine is the upregulation of the nicotinic receptor protein subunits themselves. Furthermore, following nicotine exposure, neuronal transcriptomes are altered [11–15]. However, the transcriptome-wide response to nicotine in the SNc is not clearly understood.

Parkinson's disease (PD) is currently an incurable, age-related neurodegenerative disorder. Although common, the etiology remains poorly understood [17,18]. Familial causes of PD only account for 10% of PD cases, 90% of cases appear to be sporadic, however genetic susceptibility may play a role in sporadic PD. Several genes are associated with familial forms of PD and include: Pink1 (Park6), DJ-1 (Park 7), UCHL1 (Park 5; proteasomal protein), SNCA (Park 1,4), Park2 (Parkin; a ubiquitin E2 ligase) and LRRK2 [19]. In PD there is widespread neuronal loss throughout the brain with pronounced neuronal degeneration of DA neurons of the SNc. The death of DA neurons in the SNc contributes to the loss of dopamine in the striatum, a brain region involved in the control of movement, leading to diagnostic clinical features of bradykinesia, rigidity and tremor. Interestingly, a person's history of tobacco use is inversely correlated with his/her risk of Parkinson's disease (PD) [20,21]. The protective effects of nicotine may be twofold: (1) nicotine exposure activates SNc nAChRs at the plasma membrane, increasing firing frequency and therefore increasing release of dopamine in the dorsal striatum, and (2) the distinct molecular pathways that are regulated by nicotine may exert neuroprotective effects. In addition to nicotine, smoked or smoke-cured tobacco releases numerous other components, any of which may play an additive role in protection against nigrostriatal damage [22]. This apparent neuroprotective effect of smoking has been modeled in animals, and the data show a strong protective effect of nicotine itself [23–27]. However, smoked or smoke-cured tobacco will never be a medically acceptable therapy. Therefore it is important to understand the mechanism of apparent inadvertent neuroprotective and/or therapeutic effects of chronic exposure to nicotine. In this study we wanted to develop methods to determine whether chronic nicotine-induced changes in gene expression contribute to the neuroprotective effects of nicotine. Furthermore, there may be transcriptional modifications due to nicotine exposure in the SNc in the healthy brain, and we would like to obtain a clear understanding of this.

Here we investigate the effects of chronic nicotine treatment versus saline treatment on wildtype mouse SNc neurons. We collect and pool ~20 SNc neurons using laser-capture microscopy, then assess transcriptional modifications by deep sequencing. We give the first whole-transcriptome analysis of nicotinic treatment on SNc cells. Globally, we find that the expression levels of a total of 129 genes are significantly modulated, 67 are upregulated, and 62 are downregulated, by chronic nicotine exposure in our unbiased study. Given the above described role of dopamine and nAChRs in the SNc, and the role of endoplasmic reticulum (ER) stress in PD [28–33], we first summarize the effect of nicotine on expression of dopamine-related, nicotinic receptor, and ER stress-related genes. We find that, broadly

speaking, these classes of genes are not significantly altered by chronic nicotine exposure. However, our data reveal that nicotine exposure modulates expression of 129 genes that could be relevant to the neuroprotective effects of smoking including genes involved in (1) the ubiquitin–proteasome pathway, (2) cell cycle regulation, (3) chromatin modification, and (4) DNA binding and RNA regulation. We also report the first draft transcriptome of single-cell dopaminergic and GABAergic neurons isolated from midbrain cultures. Our results give an emerging picture of the role of nicotine on the SNc and on dopaminergic neurons.

2. Materials and methods

2.1. Mice

All experiments were conducted in accordance with the guidelines for care and use of animals provided by the National Institutes of Health (NIH), and protocols were approved by the Institutional Animal Care and Use Committee at the California Institute of Technology. Mice were kept on a standard 12 h light/dark cycle at 22 °C and given food and water ad libitum. On P21, mice were weaned and housed with same-sex littermates.

2.2. Chronic nicotine administration

Chronic nicotine or saline was administered to C57BL6/DBA mice using mini-osmotic pumps (model 2002; Alzet, Cupertino, CA) for 14 days as described previously [5,34]. On the day of pump implantation, saline or (–)-nicotine hydrogen tartrate (Sigma, St. Louis) was prepared freshly and loaded into the pump to deliver nicotine at 2 mg/kg/h. This concentration has been shown to provide maximal nAChR upregulation and provides a blood concentration of 590 nM, which is near the peak concentration in the average smokers' brain [35,36]. On completion of the 14-day nicotine treatment mice were deeply anesthetized with sodium pentobarbital (100 mg/kg; i.p.) and sacrificed by decapitation. Mice were 4 months of age at the end of chronic nicotine/saline treatment.

2.3. Laser capture microdissection

Our methods pipeline for fabricating cDNA libraries via laser capture microdissection [37–39], and performing RNA-Seq are outlined in Fig. 1. Whole brains from 4 month old male mice ($n = 2$) were collected (post-mortem interval of <5 min), fresh frozen over dry-ice, and stored at –80 °C. Midbrain cryostat sections (20 μ m) were mounted on UV-treated Zeiss Membrane Slides (1.0 PEN NF), air dried for 5 min, and stained with cresyl violet for 1 min. The sections were rinsed, dried and then visualized under brightfield illumination at 400 $\times$ magnification on a Zeiss PALM Laser Capture Micro Dissection microscope. Twenty putative DA⁺ cell bodies from the SNc were dissected using multiple low laser energy pulses (see Fig. 2A), and were catapulted into Zeiss 200 μ L adhesive caps. Cell lysis solution (Illumina, San Diego, CA) containing 3' SMART reverse transcription primers and quantitation controls ("spikes") were then added into the pool of cells prior to freezing. For comparison we also generated RNA-Seq libraries from 200 pg of untreated mouse whole brain RNA ($n = 2$).

2.4. RNA-Seq library generation

To fabricate our cDNA libraries we prepared amplified cDNA from RNA, using Clontech's SMARTer™ Ultra Low RNA system for Illumina Sequencing (Clontech, Mountain View, CA). We used Clontech's Advantage 2 PCR system for the efficient and accurate amplification of cDNA templates by long-distance PCR. Epicentre's Nextera Tn5-mediated tagmentation technology (Epicenter, Madison, WI) was used as an in vitro transposition method to simultaneously fragment and tag the cDNA libraries with Illumina compatible sequencing primers. After quality control measures of yield and fragment length distribution

were taken using the Qubit fluorometer (Invitrogen, Carlsbad, CA) and the Agilent (Santa Clara, CA) Bioanalyzer, 50 bp, or 100 bp, sequencing reads were generated on the Illumina HiSeq instrument. Each sequencing library generated > 20 million uniquely mapping reads.

2.5. Computational analysis

50 bp or 100 bp sequence tags were mapped to the mouse genome using TopHat 1.3.2 [41]. We quantified transcript abundance (FPKM: fragments per kilobase per million mapped reads (expression values)) using Cufflinks. We annotated the transcripts with genome annotations provided by ENSEMBL. We conducted pairwise comparisons and calculated statistical values using Cuffdiff, part of the Cufflinks suite, to identify differentially expressed genes. We assessed ontology with DAVID [42,43]. Cuffdiff data with FPKM > 1, a corrected *p* value of <0.05 and a fold difference of >1.5 were given as input to Ingenuity Pathway Analysis (IPA) for pathway analysis. Gene expression distribution and scatter plots were generated using the R package cummeRbund [41].

2.6. Immunohistochemistry

Mice (C57BL6) (*n* = 3) were deeply anesthetized with sodium pentobarbital (100 mg/kg; i.p.) and perfused transcardially with 15 ml of ice-cold PBS followed by 25 ml of ice-cold 4% paraformaldehyde (PFA) in PBS. Brains were removed and postfixed for 2 h at 4 °C with the same fixative and cryoprotected in PBS containing 30% sucrose until the brain sank. Coronal sections (50 µm) were cut on a micro slicer and collected into a 12-well tissue culture plate containing PBS. Sections were permeabilized (20 mM HEPES, pH 7.4, 0.5% Triton X-100, 50 mM NaCl, 3 mM MgCl₂, 300 mM sucrose) for 1 h at 4 °C followed by blocking (0.1% Triton X-100, 5% donkey serum in TBS) for 1 h at RT. Slices were incubated overnight at 4 °C in solutions containing primary antibodies (diluted in 0.1% Triton X-100, 5% donkey serum in TBS). Primary antibodies and final dilutions were as follows: 1:200 rabbit anti-phospho-eIF2α, (9721; Cell Signaling), 1:500 sheep anti-tyrosine hydroxylase (TH) (AB1542; Millipore), 1:250 rabbit anti-XBP1 (sc7160; Santa Cruz), 1:50 rabbit anti-GADD153 (CHOP) (sc575; Santa Cruz Biotechnology). Sections were washed thrice for 10 min each in TBST (0.1% Triton X-100 in TBS) and incubated for 1 h at RT with secondary antibodies (diluted in 0.1% Triton X-100, 5% donkey serum in TBS). Secondary antibodies and final dilutions were as follows: 1:1000 goat anti-rabbit Alexa 488 (A11008; Invitrogen), 1:1000 donkey anti-sheep Alexa 555 (A21436; Invitrogen), 1:1000 donkey anti-mouse Alexa 555 (A31570; Invitrogen), and 1:1000 goat anti-guinea pig Alexa 555 (A21435; Invitrogen). Sections were then washed four times in TBST for 10 min each. All sections were mounted on slides and coverslipped with Vectashield (Vector Laboratories), then imaged with a Nikon Instruments C1 or A1 laser-scanning confocal microscope system equipped with spectral imaging capabilities and a Prior (Rockland) remote-focus device. A Nikon Plan Apo 10× or 60× oil immersion objective was used, and pinhole diameter was 30 µm. Sections were imaged at 12-bit intensity resolution over 512 × 512 pixels at a pixel dwell time of 2–4 µs. Alexa 488 was excited with an argon laser at 488 nm, and Alexa 555 was excited with a solid-state laser at 561 nm. Imaging was performed using the Nikon DEES grating and spectral detector with 32 parallel photomultiplier tubes. Signals from dyes were unmixed from background autofluorescence similar to our previous studies [44–47].

2.7. Cell culture and single-cell harvesting

To culture primary midbrain neurons from mouse embryos, ventral midbrain tissue from embryonic day 14 embryos was dissected out using standard procedures. Following digestion with papain (15 min at 37 °C), cells were separated by DNase treatment and trituration, and plated at a density of 100,000 cells per dish in poly-L-ornithine and laminin

coated imaging dishes containing Neurobasal medium supplemented with B27, Glutamax, 1% Hyclone equine serum and 100 μ M ascorbate. Either control medium (control) or 200 nM nicotine was added to the culture for two weeks from day 7 to day 21. Media were changed every 3 days. Single cells were harvested on day 21 following a previously reported protocol [48]. Glass capillary tubing (Kimax-51, 1.5–1.8 mm o.d.) was cleaned by sonication in ethanol and then baked overnight at 200 °C to inactivate RNAase. Large bore, glass micropipettes (10–30 μ m tip diameter) were pulled from the tubing using a Sutter P-50 microelectrode puller. Prior to harvesting, we removed the media from the culture dishes, rinsed them with 2 ml of Dulbecco's PBS, and left 1 ml of Dulbecco's PBS remaining in the dish for harvesting. Individual cultured neurons were identified using a microscope equipped with a 40 $\times$ phase objective. The pipette was positioned over the cell soma using a motorized micromanipulator (Sutter Instrument Co., USA), the cell was aspirated into the glass micropipette using gentle suction. The micropipette containing the cell was immediately removed from the bathing solution, placed inside a plastic, RNAase-free microcentrifuge tube containing 1.5 μ l of RNAase-free PBS and 0.5 μ l of an RNAase inhibitor solution, and its tip was broken against the side of the tube near the bottom. We applied outward pressure to the broken micropipette using a large gauge syringe needle to expel the remaining fluid at the tip of the micropipette into the tube. The tube was then centrifuged briefly using a desktop centrifuge and then frozen on dry ice. Typically, 16 cells were harvested per dish over a 1 h period at ambient temperature. The resultant mRNAs were reverse transcribed and amplified to construct single-neuron high-yield cDNA sequencing libraries.

3. Results

3.1. Generation of RNA-Seq libraries from 30 laser captured midbrain cells

Genome-wide transcriptomic analyses are routinely used to monitor specific tissue-, disease-, and cell-type gene expression [49], but it has been technically challenging to generate expression profiles from single cells or from a small number of cells. We first generated RNA-Seq libraries from 30 laser captured midbrain (SNc and VTA) neurons dissected from untreated mouse coronal slices (a representative image for laser capture microdissection is given in (Fig. 2A). Quality control is shown in Fig. 2B, and representative data are shown in Fig. 2C (Libraries 1–3). We obtained >30 million 50 bp reads, and detected >10,000 genes, per library, with an excellent distribution of gene expression from 0 to 5000 FPKM. For comparison, we also generated high-quality cDNA libraries from 200 pg of mouse whole brain RNA ($n = 2$); representative data are shown in Fig. 2C, Library 4. In addition to sequence-based and quantitative analysis, gene ontology bioinformatics tools were used to analyze these data. The top three gene ontology categories of the 300 most highly expressed genes in midbrain DA⁺ neurons were determined using DAVID [42,43]. The top 3 functional categories of genes are respiratory chain, metabolite/energy and mitochondrion. These functional categories comply with our expectations for dopaminergic neurons.

3.2. Enrichment of nicotinic receptor transcripts in SNc neurons compared to whole brain tissue

We next generated high-quality RNA-Seq libraries from 20 laser captured SNc cells. We conducted Cufflinks and Cuffdiff analysis [41] to compare transcript levels in SNc neurons versus whole brain tissue. Overall 1505 genes had significantly different expression in whole brain ($n = 2$) versus SNc libraries ($n = 2$); 243 genes had significantly higher expression, and 1262 had significantly lower expression, in SNc neurons as compared to whole brain (with no FPKM threshold applied). The data show that *Chrna3*, *Chrna4*, *Chrna6*, *Chrna5*, *Chrn2*, *Chrn3* and *Lynx1* transcripts are present in the SNc neurons.

These nAChR genes encode nAChR $\alpha 3$, $\alpha 4$, $\alpha 6$, $\alpha 5$, $\beta 2$, $\beta 3$ subunits, respectively, and *Lynx1* is a nicotinic receptor modulator. We compared basal transcript levels for nicotinic receptor genes from these laser captured SNc neurons to basal levels in whole brain tissue. Our data show that several nicotinic receptor gene transcripts, namely *Chrna4*, *Chrna6*, and *Chrn3*, are significantly enriched in SNc cells compared to whole brain tissue (Table 1). Here, *Chrna4* and *Chrna6* are the most abundantly expressed nicotinic receptor transcripts. We note that *Lynx1* is expressed, but not enriched, in SNc neurons. Other work shows that approximately 90% of SNc neurons are dopaminergic [50], and as expected, our data show an enrichment of tyrosine hydroxylase (TH) transcripts in the SNc neurons compared to whole brain. Tyrosine hydroxylase is enriched 61 fold (42.4 FPKM versus 2588 FPKM). We also measured an enrichment of other dopamine-related genes including Dopa decarboxylase (*Ddc*) by 84 fold, *Slc6a3* (the dopamine transporter DAT) by 207 fold, and *Drd2* (the dopamine D2 receptor) by 128 fold (Table 1).

3.3. Transcriptome-wide analysis of SNc neurons after 14 days of exposure to nicotine at 2 mg/kg/h

We assessed gene expression on laser captured SNc neurons from mice treated with either nicotine or saline, to determine the details of gene activation caused by nicotine exposure in this specific neuronal population. We laser captured 20 SNc neurons after 14 days of exposure to nicotine at 2 mg/kg/h ($n = 2$), or saline (control) ($n = 2$). In order to make a conservative analysis, we applied two criteria. (a) We analyzed data for genes in which both samples (saline and nicotine) show transcripts at a level of >1 FPKM. (b) We required that Cuffdiff determines a corrected p value of < 0.05 for significance between the two samples. With these criteria, which eliminate false positives, we find that a total of 129 genes are modulated, 67 genes are significantly upregulated, and 62 are significantly downregulated, by chronic nicotine exposure.

3.3.1. nAChR subunits—Our study reports the basal transcript expression levels of nAChR α and β subunits and *Lynx1* in SNc cells. We investigated the effects of chronic nicotine administration on SNc mRNA levels for nAChR α and β subunits. We detected no significant change in nicotinic receptor transcripts for *Chrna4*, *Chrna6*, *Chrna3*, *Chrna5*, *Chrn3* and *Chrn2* in nicotine treated versus untreated SNc neurons (Table 2). This result agrees with a previous study [51] suggesting that nicotinic receptor transcripts are not modulated by nicotine treatment. We also report that *Lynx1* is not significantly regulated by chronic nicotine treatment.

3.3.2. Nicotine does not regulate dopamine-related gene transcript levels in wildtype SNc cells—Animal studies show that the apparent neuroprotective effect of nicotine is at least partially due to nicotine itself [23–27]. We investigated whether chronic nicotine administration could modulate mRNA levels for dopamine-related genes in the SNc. We examined mRNA levels for TH, *Ddc*, *Slc6a3*, and *Drd2*. We found no significant change in dopamine-related transcript levels in nicotine treated versus untreated SNc neurons (Table 2). Hence, nicotine does not regulate gene transcription for dopamine-related genes in wildtype SNc cells.

3.3.3. Nicotine treatment does not modulate the expression of ER stress genes in SNc neurons of wildtype unstressed animals—ER stress markers have been found in human PD postmortem SNc tissue [30]; hence we were interested to test whether nicotine modulates levels of expression of ER stress-associated proteins. We first quantified basal transcript levels for ER stress genes from the laser captured SNc neurons. Table 2 presents novel basal ER stress gene transcript levels for genes from each of the 3 arms of the unfolded protein response (UPR) pathway, in the saline SNc FPKM column.

This mRNA result is concordant with our protein study for ER stress genes shown in Fig. 3. We detected protein expression for several ER stress proteins in the SNc of wildtype mice (control). In Fig. 3, protein expression for p-eIF2 α , XBP1 and CHOP, each co-stained with TH antibody, are detected in the SNc in wildtype coronal brain sections. Next we examined whether chronic nicotine treatment modulates mRNA expression of ER stress gene in wildtype unstressed SNc neurons. We show that chronic nicotine treatment does not modulate ER stress gene levels in wildtype SNc neurons (Table 2).

3.3.4. SNc neuronal-specific transcript modulations induced by chronic nicotine exposure—As noted above, we observed 129 SNc neuronal-specific transcript modulations induced by chronic nicotine exposure. Changes in transcript levels for transcription factors, enzymes, transporters and kinase peptidases and nuclear receptors were detected. We next highlight some of these results. Significant changes observed between the control and nicotine treated samples had corrected *p* values that ranged from 0.00 to 0.05, some of which are highlighted below.

Ubiquitin–proteasome pathway: Chronic nicotine exposure significantly upregulates the E2 ubiquitin ligase ubiquitin-conjugating enzyme E2J2 (UBE) by 5.06 fold (corrected *p* value = 0.03). This enzyme is located in the membrane of the endoplasmic reticulum. However, chronic nicotine exposure also significantly decreases the levels of a proteasome subunit and two de-ubiquitinating enzymes involved in the ubiquitin–proteasome pathway. For example, chronic nicotine significantly decreases the transcript levels of the proteasome (prosome, macropain) activator subunit 2 (PSME2) by 23.27 fold (corrected *p* value = 0.01) and of the ubiquitin specific peptidase 16 (USP16) gene by 26.89 fold (corrected *p* value = 0.026) and the ubiquitinating specific peptidase 34 (USP34) gene by 10.89 fold (corrected *p* value = 0.025). Both latter genes encode de-ubiquitinating (DUB) enzymes.

Cell cycle regulators: Chronic nicotine exposure effects the expression of two cell cycle regulators: it significantly upregulates cell division cycle 26 (CDC26) by 9.93 fold (corrected *p* value = 0.03) and significantly downregulates cell division cycle 23 (CDC23) by 26.58 fold (corrected *p* value = 0.02). Both CDC proteins have ubiquitin–protein ligase activity.

Chromatin modification: Chronic nicotine exposure significantly upregulates the expression of chromodomain helicase DNA binding protein 4 (CHD4) by 24.4 fold (corrected *p* value = 0.04). CHD4 has DNA methylation and transcriptional repression activity.

DNA binding and regulation of transcription: Zinc finger protein 76 (ZNF76/Zfp523) and zinc finger with UFM1-specific peptide domain (Zufsp) are both significantly downregulated by nicotine by 43 fold (corrected *p* value = 0.04) and 5.49 fold (corrected *p* value = 0.04) and play a role in DNA binding and regulation of transcription.

RNA processing: Chronic nicotine exposure significantly upregulates the expression of polynucleotide adenylyltransferase, poly(A) polymerase alpha (PAPOLA) by 13.1 fold (corrected *p* value = 0.04). It is involved in the processing of RNA and plays a role in cleavage and polyadenylation of pre-mRNA.

3.4. Novel single-cell DA and GABAergic transcriptomics

We aspirated a single neuron from primary mouse midbrain cultures into a glass pipette made in a patch-clamp pipette puller. The resultant mRNAs were reverse transcribed and amplified to generate a single-neuron, high-yield, good-quality cDNA library. We detected

~5000 genes in the single cell libraries. In our midbrain cultures it was not possible to distinguish visually among GABAergic and dopaminergic neurons. However, the RNA-Seq data show that single-cell transcriptomics unambiguously distinguishes GABAergic from dopaminergic neurons. Discrimination is accomplished by quantifying the mRNA levels of the DA⁺ marker gene TH and the GABAergic marker gene Gad1 in the single-cell libraries. To the best of our knowledge this is the first time single cell RNA-Seq libraries have been generated from DA and GABAergic neurons. We present RNA-Seq data for the dopamine-related genes TH, DDC and Slc6a3, and for the GABAergic marker gene Gad1, in two single DA⁺ neurons ($n = 1$ control media, $n = 1$ nicotine-treated) (Table 3) and in six GABAergic neurons ($n = 4$ control media, $n = 2$ nicotine-treated) (Table 4). We also report the transcript levels of Chrna6 and Chrnb3 and ER stress genes involved in each of the three arms of the UPR in the two single DA⁺ neurons and in the six GABAergic neurons. We report Cufflinks FPKM data in Tables 3 and 4. We observe variability in transcript levels for our genes of interest. We also ran Cuffdiff analysis on the GABAergic (control) libraries and listed each of the 4 (control) libraries as a biological replicate versus the two nicotine treated cells. The Cuffdiff analysis indicates that nicotine treatment does not regulate ER stress genes. We do not report Cuffdiff analysis on our control versus nicotine-treated dopaminergic neurons as our dopaminergic cell number is too small and we wish to avoid any unwarranted interpretations.

We employ a scatter plot to assess cell heterogeneity between two (control) non-treated GABAergic libraries (Fig. 4A). The GABAergic single cell RNA-Seq data clearly show heterogeneity in expression profiles between single cells of the same type (Fig. 4A). A Pearson's correlation analysis on two control GABAergic cell transcriptomes gives $r = 0.61$ (not shown). We employ distribution plots to compare the expression density/abundance in these two GABAergic cells. For both cells, we observe a broad distribution of transcript expression over 6 orders of magnitude (Fig. 4B).

In summary, we have compiled the first draft transcriptome for dopaminergic and GABAergic neurons isolated from midbrain cultures and the main genes of interest are summarized in Tables 3 and 4. Our future work will further map out single-cell molecular variability (and similarity) associated with cell phenotypes and this will also further highlight cellular pathways that are modulated by nicotine at the single-cell level.

4. Discussion

We have developed a method for assessing the effects of chronic nicotine exposure on gene expression in SNc neurons. We have successfully combined laser capture microscopy and single cell transcriptomics. We also present initial data from the method. We observed 129 SNc neuronal-specific transcript modulations induced by chronic nicotine exposure. We discuss the relevance of these findings below.

4.1. Nicotine affects transcript levels of ubiquitin–proteasome genes in SNc cells; relevance to Parkinson's disease?

In all tissues, the majority of intracellular proteins are degraded by the ubiquitin–proteasome pathway [52,53]. The ubiquitin–proteasome pathway contains enzymes (E1, E2 and E3) that link ubiquitin chains onto proteins to mark them for degradation by the 26S proteasome [53]. Here, we show for the first time that nicotine modulates the transcript levels of ubiquitin enzymes and proteasome in SNc neurons. Specifically, we find that an E2 ligase UBE2J2, and a proteasome subunit (PSME2), and two de-ubiquitinating enzymes (USP16 and USP34) are significantly modulated by nicotine exposure. As mentioned earlier mutations in the proteasomal gene UCHL1 (Park 5; proteasomal protein) or in Park2 (Parkin; a ubiquitin E2 ligase) are associated with familial forms of PD. In both sporadic and

familial PD, SNc dopaminergic cells show proteasome dysfunction [54–60]. However, there is an inverse correlation between PD and person's history of smoking. It is not unreasonable to suggest that the modulation of the ubiquitin proteasome pathway may contribute to the putative neuroprotective effects of nicotine and may warrant further investigation.

Previously Kane et al. [61] showed that, after exposure to nicotine for 14 days, ubiquitin enzymes, 20S and 19S proteasomal subunits, and chaperonin-containing complex members are upregulated in 2 mm tissue punches from the rat prefrontal cortex (PFC) and are downregulated in tissue punches taken from the medial basal hypothalamus (MBH). Interestingly, their study makes it clear that ubiquitin–proteasome pathways in different brain regions have different responses to nicotine. However, such regional brain tissue samples are extremely heterogeneous containing hundreds, or perhaps thousands, of cells, with different cell types represented in varying proportions. This makes it challenging to make cell-type specific inferences. We overcame this challenge by conducting RNA-Seq on a small number of cells, from the SNc, dissected from their in situ environment. This allows us to infer that ubiquitin–proteasome transcripts are regulated in dopaminergic neurons of the SNc, a result that may be of relevance to the putative neuroprotective effect of nicotine on the SNc.

In addition to the ubiquitin–proteasome pathway chronic nicotine also significantly modulates other genes that could be relevant to the neuroprotective effects of smoking including genes involved in cell cycle regulation, chromatin modification, and DNA binding and RNA regulation.

The literature contains many discussions on the relative importance of pulsatile (smoked) versus continued application of nicotine. Our preliminary data cannot settle this point. However we note these arguments for the relevance of continued application: (1) chewed tobacco, which induces brain nicotine levels more slowly than smoking, also has an apparent protective effect, (2) upregulation, the best-studied cellular effect of chronic nicotine exposure, occurs quite robustly with all tested means of nicotine exposure, including smoking, oral administration, and minipumps.

4.2. Chronic nicotine exposure does not regulate nAChR or dopamine-related gene mRNA levels in SNc cells

As discussed earlier, the degeneration of DA neurons in the SNc contributes to the loss of dopamine in the striatum, a brain region involved in the control of movement, leading to diagnostic clinical features of bradykinesia, rigidity and tremor. One protective effect of nicotine may be that nicotine exposure activates SNc nAChRs at the plasma membrane, increasing firing frequency and therefore increasing release of dopamine in the dorsal striatum. Here in this study, we were interested to know if chronic nicotine exposure induces changes in expression levels of nAChR and dopaminergic related genes. Our data show that in SNc cells chronic nicotine exposure does not regulate nAChRs mRNA levels or transcript levels of dopamine-related genes. These results are concordant with Marks et al. [51]. We also report that the mRNA expression of *Lynx1* is not modulated by chronic nicotine exposure.

4.3. Basal levels of ER stress gene transcripts in healthy SNc cells

Nicotine-induced relief of endoplasmic reticulum (ER) stress has been postulated as a potential mechanism for the neuroprotective effects of smoking. Our study assesses whether chronic nicotine significantly affects the expression of ER stress-related genes. Our study reveals the basal level of ER stress gene transcripts in healthy SNc neurons isolated from intact brains. We also find that chronic nicotine exposure does not regulate ER stress gene

transcript levels in healthy SNc neurons. However, it is possible that ER stress levels may increase in the SNc of PD brains caused by protein misfolding and high cellular levels of α -synuclein and other PD-related proteins. Indeed higher levels of ER stress markers are seen in PD post mortem studies [30]. The putative neuroprotective effects provided by nicotine may be cumulative over decades and contribute to a prevention of ER stress build-up. If this process occurs, it could contribute to the inverse correlation of PD and a person's history of smoking. Therefore, investigating ER stress gene transcripts levels in SNc cells isolated from a PD model that shows dopaminergic cellular dysfunction is warranted.

4.4. Single cell transcriptomics

4.4.1. Single cell transcriptome variability—Recently it has become feasible to measure cell type specific expression [62–64]. Substantial differences in gene expression have been shown for individual cells, even when those cells are taken from a seemingly homogenous population [65–70]. Here we use single cell RNA-seq to investigate the affects of chronic nicotine on GABAergic and dopaminergic neurons isolated from midbrain cultures. We also use this newly developed technique to assess the heterogeneity in neuronal populations. We employ a scatter plot to assess the global similarity and differences between our GABAergic (control) libraries (Fig. 4A). Shalek et al. [65] observed that correlation analysis of transcript expression levels between two 10,000–cell population replicates gave $r = 0.98$ showing low heterogeneity. However, gene expression differences between individual cells are averaged out in such bulk preparation comparisons. In contrast a comparison of two single immune cells gave $r = 0.54$, showing high heterogeneity [65]. Here we observe that Pearson's correlation analysis of transcript expression levels of two single GABAergic cells gave $r = 0.61$. Molecular and physiological diversity of midbrain GABAergic neurons has been highlighted by [71]. As discussed in [65], potential influences on single cell heterogeneity include the source of the analyzed cells (in vitro versus ex vivo), the biological condition of the individual cells, the cellular microenvironment, and of course short bursts of RNA transcription. Variance in gene expression measurements is also influenced by the technical difficulty of capturing minute quantities of mRNA in single cell samples.

4.4.2. Effects of nicotine on ER stress genes in single GABAergic neurons—

We find that chronic nicotine exposure does not regulate ER stress gene transcript levels in GABAergic neurons. This result is concordant with our LCM-captured SNc libraries.

4.5. Concluding remarks

This study highlights the fact that chronic nicotine exposure has a notable effect on the SNc transcriptome, modulating 129 genes and affecting the role of central cellular pathways. These effects may contribute to the putative neuroprotective role of nicotine and may be relevant to PD. More generally, these results reveal the transcriptional effects of nicotine on the brain.

Clinical trials of nicotine patches in early-stage PD have yielded mixed results, and additional trials are under way. We wish to point out the major difference between identifying a target—for instance, nAChRs—and understanding the mechanism. The mechanism includes the very important question of the target's localization (ER versus plasma membrane; see graphical abstract), as the dosing/pharmacokinetic considerations for subcellular action differ greatly from those for plasma membrane action. Specifically, nicotine upregulates nAChRs by pharmacological chaperoning at much lower concentrations than those appropriate for activation. Mechanism also includes the signaling pathways engaged (see graphical abstract); such knowledge will be required both to specify additional drugs that might enhance nicotine neuroprotection, and to design suitable analogs that might

be more protective than nicotine itself. Only by understanding mechanistic points will the community be able to leverage the broad hint from nicotine's apparent neuroprotective action.

Acknowledgments

We thank Igor Antoshechkin for library sequencing, sequencing facility management and for computational training, Sheri McKinney for excellent cell cultures and for conducting nicotine administration, and Purnima Deshpande for animal breeding and laboratory management. We thank Prof. John Allman for use of the Zeiss laser capture microscope, Georgi Marinov for some analysis and helpful discussions and Charlotte Yang for initial DAVID analysis. This work was supported by the NIH (DA017279, AG033954), by the California Tobacco-Related Disease Research Program, by the Caltech Innovation Initiative, by the Conte Center (MH086383), and by the Millard and Muriel Jacobs Genetics and Genomics Laboratory at California Institute of Technology. We thank the reviewers for helpful and insightful comments.

Abbreviations

DAVID	Database for Annotation, Visualization and Integrated Discovery
ER	endoplasmic reticulum
FPKM	fragments per kilobase per million mapped reads
IPA	Ingenuity Pathway Analysis
nAChR	nicotinic acetylcholine receptor
PD	Parkinson's disease
SNC	substantia nigra pars compacta
UPR	unfolded protein response
VTA	ventral tegmental area

References

1. Research for International Tobacco Control. WHO report on the global tobacco epidemic, 2008: the MPOWER package. World Health Organization; 2008.
2. Barik, J.; Wonnacott, S. Molecular and cellular mechanisms of action of nicotine in the CNS. In: Henningfield, J.; London, E.; Pogun, S., editors. *Nicotine Psychopharmacology*. Berlin, Heidelberg: Springer; 2009. p. 173-207.
3. Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. *Handbook of Experimental Pharmacology*. 2009;29–60. [PubMed: 19184645]
4. Drenan RM, Nashmi R, Imoukhuede PI, Just H, McKinney S, Lester HA. Subcellular trafficking pentameric assembly subunit stoichiometry of neuronal nicotinic ACh receptors containing fluorescently-labeled $\alpha 6$ and $\beta 3$ subunits. *Molecular Pharmacology*. 2008; 73:27–41. [PubMed: 17932221]
5. Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, et al. Chronic nicotine cell specifically upregulates functional $\alpha 4^*$ nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. *The Journal of Neuroscience The Official Journal of the Society for Neuroscience*. 2007; 27:8202–18. [PubMed: 17670967]
6. Nashmi R, Dickinson ME, McKinney S, Jareb M, Labarca C, Fraser SE, et al. Assembly of $\alpha 4\beta 2$ nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. *The Journal of Neuroscience The Official Journal of the Society for Neuroscience*. 2003; 23:11554–67. [PubMed: 14684858]
7. Srinivasan R, Pantoja R, Moss FJ, Mackey ED, Son CD, Miwa J, et al. Nicotine up-regulates $\alpha 4\beta 2$ nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. *Journal of General Physiology*. 2011; 137:59–79. [PubMed: 21187334]

8. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of $\alpha 4^*$ receptors: sufficient for reward, tolerance and sensitization. *Science*. 2004; 306:1029–32. [PubMed: 15528443]
9. Penton RE, Lester RAJ. Cellular events in nicotine addiction. *Seminars in Cell & Developmental Biology*. 2009; 20:418–31. [PubMed: 19560047]
10. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. *Physiological Reviews*. 2009; 89:73–120. [PubMed: 19126755]
11. Brunzell DH, Russell DS, Picciotto MR. In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. *Journal of Neurochemistry*. 2003; 84:1431–41. [PubMed: 12614343]
12. Brunzell DH, Mineur YS, Neve RL, Picciotto MR. Nucleus accumbens CREB activity is necessary for nicotine conditioned place preference. *Neuropsychopharmacology Official Publication of the American College of Neuropsychopharmacology*. 2009; 34:1993–2001. [PubMed: 19212318]
13. Madsen HB, Brown RM, Lawrence AJ. Neuroplasticity in addiction: cellular and transcriptional perspectives. *Frontiers in Molecular Neuroscience*. 2012; 5:99. [PubMed: 23162427]
14. Flatscher-Bader T, Wilce PA. The effect of alcohol and nicotine abuse on gene expression in the brain. *Nutrition Research Reviews*. 2009; 22:148–62. [PubMed: 19900347]
15. Nestler EJ. Transcriptional mechanisms of addiction: role of Δ FosB. *Philosophical Transactions of the Royal Society B Biological Sciences*. 2008; 363:3245.
16. Miwa JM, Freedman R, Lester HA. Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. *Neuron*. 2011; 70:20–33. [PubMed: 21482353]
17. Meredith GE, Sonsalla PK, Chesselet M-F. Animal models of Parkinson's disease progression. *Acta Neuropathologica*. 2008; 115:385–98. [PubMed: 18273623]
18. Chesselet M-F, Richter F. Modelling of Parkinson's disease in mice. *The Lancet Neurology*. 2011; 10:1108–18.
19. Nestler, EJ.; Hyman, SE.; Malenka, RC. *Molecular neuropharmacology: a foundation for clinical neuroscience*. New York: McGraw-Hill, Medical Pub. Division; 2001.
20. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. *Archives of Neurology*. 2007; 64:990–7. [PubMed: 17620489]
21. Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. *Neurology*. 2007; 68:764–8. [PubMed: 17339584]
22. Quik M, Wonnacott S. $\alpha 6\beta 2^*$ and $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors as drug targets for Parkinson's disease. *Pharmacological Reviews*. 2011; 63:938–66. [PubMed: 21969327]
23. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. *Movement Disorders Official Journal of the Movement Disorder Society*. 2012; 27:947–57. [PubMed: 22693036]
24. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental Parkinsonism in rodents and induces striatal increase of neurotrophic factors. *Journal of Neurochemistry*. 1998; 71:2439–46. [PubMed: 9832142]
25. Costa G, Abin-Carriquiry JA, Dajas F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. *Brain Research*. 2001; 888:336–42. [PubMed: 11150495]
26. Ryan RE, Ross SA, Drago J, Loiacono RE. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in $\alpha 4$ nicotinic receptor subunit knockout mice. *British Journal of Pharmacology*. 2001; 132:1650–6. [PubMed: 11309235]
27. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. *Journal of Neurochemistry*. 2006; 98:1866–75. [PubMed: 16882311]
28. Mercado G, Valdes P, Hetz C. An ERcentric view of Parkinson's disease. *Trends in Molecular Medicine*. 2013; 19:165–75. [PubMed: 23352769]

29. Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. *Cell Death and Differentiation*. 2006; 13:385–92. [PubMed: 16397584]
30. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson's disease. *Biochemical and Biophysical Research Communications*. 2007; 354:707–11. [PubMed: 17254549]
31. Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. *Journal of Cellular and Molecular Medicine*. 2011; 15:2025–39. [PubMed: 21722302]
32. Stefani IC, Wright D, Polizzi KM, Kontoravdi C. The role of ER stress-induced apoptosis in neurodegeneration. *Current Alzheimer Research*. 2012; 9:373–87. [PubMed: 22299619]
33. Song L, De Sarno P, Joje RS. Central role of glycogen synthase kinase-3 β in endoplasmic reticulum stress-induced caspase-3 activation. *The Journal of Biological Chemistry*. 2002; 277:44701–08. [PubMed: 12228224]
34. Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, Lester HA. Chronic nicotine selectively enhances $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. *The Journal of Neuroscience The Official Journal of the Society for Neuroscience*. 2009; 29:12428–39. [PubMed: 19812319]
35. McCallum SE, Parameswaran N, Bordia T, Fan H, McIntosh JM, Quik M. Differential regulation of mesolimbic $\alpha 3^*/\alpha 6^*\beta 2$ and $\alpha 4^*\beta 2$ nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys. *Journal of Pharmacology and Experimental Therapeutics*. 2006; 318:381–8. [PubMed: 16622038]
36. Marks MJ, Rowell PP, Cao JZ, Grady SR, McCallum SE, Collins AC. Subsets of acetylcholine-stimulated $^{86}\text{Rb}^+$ efflux and ^{125}I -epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. *Neuropharmacology*. 2004; 46:1141–57. [PubMed: 15111021]
37. Boone DR, Sell SL, Hellmich HL. Laser capture microdissection of enriched populations of neurons or single neurons for gene expression analysis after traumatic brain injury. *Journal of Visualized Experiments*. 2013; 74(e50308):1–7.
38. Pietersen CY, Lim MP, Macey L, Woo TU, Sonntag KC. Neuronal type-specific gene expression profiling and laser-capture microdissection. *Methods in Molecular Biology (Clifton NJ)*. 2011; 755:327–43.
39. Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, et al. Nuclei and subnuclei gene expression profiling in mammalian brain. *Brain Research*. 2002; 943:38–47. [PubMed: 12088837]
40. Watkins, S. Cryosectioning Current protocols in cytometry. Paul Robinson, J., managing editor, et al., editors. Vol. Chapter 12. 2009. p. 5
41. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nature Protocols*. 2012; 7:562–78.
42. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols*. 2009; 4:44–57.
43. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Research*. 2009; 37:1–13. [PubMed: 19033363]
44. Mackey ED, Engle SE, Kim MR, O'Neill HC, Wageman CR, Patzlaff NE, et al. $\alpha 6^*$ nicotinic acetylcholine receptor expression and function in a visual salience circuit. *The Journal of Neuroscience The Official Journal of the Society for Neuroscience*. 2012; 32:10226–37. [PubMed: 22836257]
45. Briggs CA, Gubbins EJ, Marks MJ, Putman CB, Thimmapaya R, Meyer MD, et al. Untranslated region-dependent exclusive expression of high-sensitivity subforms of $\alpha 4\beta 2$ and $\alpha 3\beta 2$ nicotinic acetylcholine receptors. *Molecular Pharmacology*. 2006; 70:227–40. [PubMed: 16569710]
46. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, et al. In vivo activation of midbrain dopamine neurons via sensitized, high-affinity $\alpha 6$ nicotinic acetylcholine receptors. *Neuron*. 2008; 60:123–36. [PubMed: 18940593]

47. Drenan RM, Nashmi R, Imoukhuede P, Just H, McKinney S, Lester HA. Subcellular trafficking, pentameric assembly, and subunit stoichiometry of neuronal nicotinic acetylcholine receptors containing fluorescently labeled $\alpha 6$ and $\beta 3$ subunits. *Molecular Pharmacology*. 2008; 73:27–41. [PubMed: 17932221]
48. Morris J, Singh JM, Eberwine JH. Transcriptome analysis of single cells. *Journal of visualized experiments*. 2011; 50(e2634):1–8.
49. Ramskold D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. *Nature Biotechnology*. 2012; 30:777–82.
50. Hnasko TS, Hjelmstad GO, Fields HL, Edwards RH. Ventral tegmental area glutamate neurons: electrophysiological properties and projections. *The Journal of Neuroscience The Official Journal of the Society for Neuroscience*. 2012; 32:15076–85. [PubMed: 23100428]
51. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. *The Journal of Neuroscience The Official Journal of the Society for Neuroscience*. 1992; 12:2765–84. [PubMed: 1613557]
52. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell*. 1994; 78:761–71. [PubMed: 8087844]
53. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin–proteasome pathway in normal and disease states. *Journal of the American Society of Nephrology*. 2006; 17:1807–19. [PubMed: 16738015]
54. Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. *Journal of Neurology Neurosurgery and Psychiatry*. 1989; 52:67–71.
55. Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. *The Journal of Pathology*. 1990; 161:153–60. [PubMed: 2166150]
56. Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. *Journal of Neuropathology and Experimental Neurology*. 1997; 56:125–31. [PubMed: 9034365]
57. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of α -synuclein toxicity in a *Drosophila* model for Parkinson's disease. *Science (New York NY)*. 2002; 295:865–8.
58. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome α -subunits in the substantia nigra pars compacta in Parkinson's disease. *Neuroscience Letters*. 2002; 326:155–8. [PubMed: 12095645]
59. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. *The American Journal of Pathology*. 2002; 160:1655–67. [PubMed: 12000718]
60. Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson's disease. *Cold Spring Harbor Perspectives in Medicine*. 2012; 2:a009423. [PubMed: 22553500]
61. Kane JK, Konu O, Ma JZ, Li MD. Nicotine coregulates multiple pathways involved in protein modification/degradation in rat brain. *Brain Research Molecular Brain Research*. 2004; 132:181–91. [PubMed: 15582157]
62. Nelson SB, Hempel C, Sugino K. Probing the transcriptome of neuronal cell types. *Current Opinion in Neurobiology*. 2006; 16:571–6. [PubMed: 16962313]
63. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. *Brain A Journal of Neurology*. 2009; 132:1795–809. [PubMed: 19052140]
64. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1 α , a potential therapeutic target for early intervention in Parkinson's disease. *Science Translational Medicine*. 2010; 2:52ra73.

65. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. *Nature*. 2013; 498:236–40. [PubMed: 23685454]
66. Bengtsson M, Stahlberg A, Rorsman P, Kubista M. Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mRNA levels. *Genome Research*. 2005; 15:1388–92. [PubMed: 16204192]
67. Raj A, van Oudenaarden A. Single-molecule approaches to stochastic gene expression. *Annual Review of Biophysics*. 2009; 38:255–70.
68. Kalisky T, Blainey P, Quake SR. Genomic analysis at the single-cell level. *Annual Review of Genetics*. 2011; 45:431–45.
69. Feinerman O, Jentsch G, Tkach KE, Coward JW, Hathorn MM, Sneddon MW, et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. *Molecular Systems Biology*. 2010; 6:437. [PubMed: 21119631]
70. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, et al. Dynamic proteomics of individual cancer cells in response to a drug. *Science (New York NY)*. 2008; 322:1511–6.
71. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. *The Journal of Neuroscience The Official Journal of the Society for Neuroscience*. 2001; 21:1452–63. [PubMed: 11222635]

Fig. 1. Methods pipeline, as performed in our experiments: (1) dissect out mouse brain, freeze (PMI < 5 min), (2) cryostat section at 20 μ m (image [40]), (3) mount on PEN slide, stain with Cresyl Violet, rinse, (4) laser capture micro dissection on Zeiss PALM, (5) lyse cells with lysis buffer with dT primer at 72 $^{\circ}$ C, (6) SMART cDNA synthesis; 22 cycles amplification, (7) transposon-mediated "tagmentation" of cDNA, (8) cDNA quality control check and multiplexed sequencing on Illumina HiSeq and (9) subsequent computational analysis using Tophat, Cufflinks and Cuffdiff [41].

Fig. 2.

(A) Representative image of laser captured SNc neurons, and neurons marked for capture (from a 20 μm coronal section stained with Cresyl violet, scale bar = 80 μm), (B) quality check of cDNA, bioanalyser electropherogram showing that most of the cDNA has length >700 bp, and (C) gene abundance in cDNA libraries from laser-capture microdissection (LCM) of midbrain neurons (SNc and VTA) and whole brain tissue. Libraries #1–3 were each generated from 30 LCM neurons; #4 from whole brain mRNA. These libraries have excellent representation: >10,000 genes are detected at >5 fragments per kilobase of transcript per million fragments sequenced (FPKM). Abundance for the three LCM libraries compares well with whole brain material.

Fig. 3. TH immunostaining and ER stress proteins in SNc neurons. Representative images of CHOP, TH, XBP1 and p-eIF2 α protein expression in wildtype coronal brain sections are shown. The top panel shows CHOP (red), TH (green) and co-stained (merge) protein expression in SNc neurons (60 $\times$, scale bars, 50 μ m). The top rightmost image shows CHOP (red) protein expression in the SNc and SNr, (10 $\times$, scale bar, 200 μ m). The middle horizontal panel shows XBP1 (green), TH (red) and merged protein expression in SNc neurons (60 $\times$, scale bar, 50 μ m). The lower panel shows p-eIF2 α (green), TH (red) and merged protein expression in SNc neurons (60 $\times$, scale bars, 50 μ m).

Fig. 4. Single-cell RNA-Seq analysis of GABAergic neurons: (A) correlation of transcript expression levels between two single GABAergic cells (cell (v) and cell (vi)) reveals substantial transcriptome heterogeneity and (B) distribution plots of gene expression reveal a broad range of expression levels.

Table 1

Enrichment of some nicotinic receptor transcripts and dopamine-related transcripts in 20 SNc neurons ($n = 2$) compared to whole brain tissue ($n = 2$). Cuffdiff was used to calculate expression (FPKM) levels in laser captured SNc neurons vs whole brain tissue. Observed differences in gene expression levels between samples are considered statistically significant if the corrected p value is <0.05 .

Gene name	Whole brain (FPKM)	Laser captured SNc neurons (FPKM)	Significant
<i>Nicotinic receptors</i>			
Chrna4	3.7	93.9	Yes
Chrna6	1.3	64.9	Yes
Chrnb3	0.29	28.4	Yes
Chrna3	0.27	5.4	No
Chrna5	0.02	0.51	No
Chrnb2	2.76	3.91	No
Chrnb4	3.25	0	No
<i>Nicotinic receptor modulator</i>			
Lynx1	33.1	15.6	No
<i>Dopamine related</i>			
TH	42.4	2588	Yes
Ddc	30.4	2560	Yes
Slc6a3/DAT1	4.8	993	Yes
Drd2	0.44	56	Yes

Table 2

The effect of nicotine on expression of selected genes in the SNc. Cuffdiff was used to calculate expression (FPKM) levels in 20 laser captured SNc neurons from saline-treated ($n = 2$) vs nicotine-treated ($n = 2$) mice. Observed differences in gene expression levels between samples are considered statistically significant if the corrected p value is <0.05 .

Gene name	Saline SNc (FPKM)	Nicotine SNc (FPKM)	Significant
<i>Nicotinic receptors</i>			
Chrna4	94.0	83.5	No
Chrna6	65.0	143	No
Chrb2	3.9	3.2	No
Chrb3	28.4	63.9	No
Chrna5	0.51	3.2	No
Chrna3	5.36	3.81	No
<i>Nicotinic receptor modulator</i>			
Lynx1	15.7	17.2	No
<i>Dopamine related</i>			
TH	2588	2622	No
Ddc	2561	3407	No
Slc6a3/DAT1	923	1447	No
Drd2	55.9	7.6	No
<i>ER stress related</i>			
Hspa5/BIP	45.1	205	No
Xbp1	93.4	52.4	No
Eif2ak3/PERK	2.1	2.5	No
Eif2s1/Elf2 α	16.1	19.7	No
ATF4	48.2	53.2	No
ATF6	0.64	0.35	No
Ddit3/CHOP(10)	86.8	110	No
<i>Ubiquitin-proteasome pathway</i>			
Ube2j2	6.43	32.6	Yes
Psme2	76.8	3.3	Yes
Usp16	110	4.1	Yes
Usp34	158	14.5	Yes
<i>ER-Golgi trafficking</i>			
Copa (COPI)	5.86	46.8	No
Sec24c	1.93	2.56	No
Sec23a	51.7	42.6	No
Sec31a	18.9	12.7	No
Sar1b	124	123	No

Table 3

Single-cell RNA-Seq data distinguishes DA⁺ from GABA neurons. Single cells were harvested on day 21 by aspirating a single neuron from primary midbrain cultures into a glass pipette. The resultant mRNAs were reverse transcribed and amplified to construct a single-neuron high-yield cDNA sequencing library. Either 200 nM nicotine or control medium was added to primary midbrain cultures for 2 weeks, from day 7 to day 21. Neuron with cell ID (i) was harvested from a control culture, and the neuron with cell ID (ii) was harvested from a nicotine treated culture. RNA-Seq data show both neurons had high levels of DA⁺ related gene transcripts, with low levels of the GABAergic marker gene Gad1. RNA-Seq (Cufflinks) data are shown for dopamine-related, GABAergic, nicotinic receptor and ER stress related transcripts. No Cuffdiff comparative analysis was conducted on this low number of cells to avoid unwarranted interpretations.

Cell ID #	(i)	(ii)
Nicotine 2 wk	–	+
Putative cell type	DA	DA
Gene name	FPKM	
<i>Dopamine related</i>		
TH	553	10,564
Ddc/DOPA decarboxylase	2756	317
Slc6a3/DAT1	1006	188
<i>GABAergic</i>		
Gad1	3.4	2.9
<i>Nicotinic receptors</i>		
Chrna6 α6	592	88.5
Chrnβ3 β3	10.2	38.1
<i>ER stress related</i>		
Hspa5/BIP	858	2.2
Xbp1	955	1.1
Eif2ak3/PERK	0.00	0.00
Eif2s1/Elf2α	0.25	158
ATF4	138	1.7
ATF6	10.5	0.02
Ddit3/CHOP(10)	714	1563

Table 4

Single-cell RNA-Seq data from GABA neurons. Single cells were harvested on day 21 by aspirating a single neuron from primary midbrain cultures into a glass pipette. The resultant mRNAs were reverse transcribed and amplified to construct a single-neuron high-yield cDNA sequencing library. Either 200 nM nicotine or control medium was added to primary midbrain cultures for 2 weeks, from day 7 to day 21. Neurons (iii), (iv), (v) and (vi) were harvested from a control culture, and neurons (vii) and (viii) were harvested from a nicotine treated culture. RNA-Seq data show that these neurons have high levels of the GABAergic marker gene *Gad1*. RNA-Seq data are shown for GABAergic, dopamine-related, nicotinic receptor and ER stress related transcripts.

Cell ID #	(iii)	(iv)	(v)	(vi)	(vii)	(viii)
Nicotine 2 wk	–	–	–	–	+	+
Putative cell type	GABA	GABA	GABA	GABA	GABA	GABA
Gene name						
<i>GABAergic</i>						
<i>Gad1</i>	424	1652	436	222	218	286
<i>Dopamine related</i>						
<i>TH</i>	23.9	21.2	0.00	0.04	0.00	2.0
<i>Ddc/DOPA decarboxylase</i>	12.3	13.4	0.00	0.3	554	2.7
<i>Slc6a3/DAT1</i>	4.2	3.5	0.00	0.00	0.00	0.9
<i>Nicotinic receptors</i>						
<i>Chna6 α6</i>	1.1	0.93	0.00	0.00	0.00	124
<i>Chnb3 β3</i>	0.10	0.12	0.00	0.00	0.00	0.07
<i>ER stress related</i>						
<i>Hspa5/BIP</i>	62.4	364	179	559	290	1.2
<i>Xbp1</i>	2.0	90.2	152	12	0.06	0.03
<i>Elf2ak3/PERK</i>	0.01	4.8	0.00	0.00	0.00	0.01
<i>Elf2s1/Elf2α</i>	0.19	0.15	0.00	0.00	0.00	0.00
<i>ATF4</i>	5.0	938	0.00	0.00	0.00	52.5
<i>ATF6</i>	0.01	0.04	0.06	75.3	0.04	0.00
<i>Ddit3/CHOP(10)</i>	5.0	2.1	288	459	437	0.73